Could cannabis legalization stall globally?

According to a recent update, around 100 items have been banned by food inspectors in the UK. According to Hemp Today, the restricted list includes three CBD oil extractions made by Colorado-based label Charlotte’s Web, while hundreds more have been approved for ingestion.

The products were removed from a public list of over 12,000 accepted for review earlier this year in the early stages of the regulator’s new or “novel” food approval process. According to a summary of the removals published by UK website BusinessCann, the Food Standards Agency (FSA) began removing products as early as March, with the latest removal occurring at the end of September.

The FSA’s innovative food division tackles the CBD gray market that has grown and is putting consumers at risk. The review offers a golden opportunity for CBD manufacturers already selling goods on the UK gray market to become fully legal. Under FSA regulations, the goods must no longer be available to customers.

Although the United Kingdom lags behind the United States and much of Western Europe when it comes to providing residents with legal access to marijuana in some form, the country is in the midst of a CBD boom. That means the UK CBD market, which could be worth $1 billion, will appeal to hemp manufacturers and producers who have noticed their opportunities in Canada, the United States and elsewhere are slipping.

However, most of the island’s hemp-derived goods, which contain the non-intoxicating cannabinoid, are unregulated. Manufacturers wishing to legally sell their products in the afterlife must obtain government approval.

According to BusinessCann, over 12,000 manufacturers of CBD products submitted claims to the British Food Standards Agency (FSA).

There are no explanations.

About 100 goods were disqualified by the agency for “a variety of reasons” that were not disclosed.

“We do not disclose information as to why specific items are being removed from the list,” a spokesperson told BusinessCann, “but the removal may be due to a variety of reasons, such as those consistent with other areas of food law.”

The FSA does not give reasons for the exclusion of individual products. Nonetheless, certain stakeholders have objected that many of the products have been withdrawn by February 13, 2020, a preliminary requirement in the evaluation process. Products remaining in the public database must have been on the market at that time, so they can remain on the market pending other decisions based on toxicity and other technical standards, which is the 2nd phase of the certification process .

According to the FSA, products can be withdrawn from the public list due to duplication, on the instruction of the applicant or due to other factors that result in them not being compliant with UK food law. However, observers hypothesized that the reasons could be CBD dosages above the UK recommended daily dose of 75 milligrams. However, products must have been marketed prior to February 2020 to be certified through this process.

Manufacturers of CBD face difficulties

The UK and global CBD producers are eager to enter the UK market, which according to some experts is currently the second largest in the world; The market is expected to reach $1 billion in the coming years. However, the FSA approval process has been extended and is expected to take two years or more at the current rating level.

The FSA was bombarded with CBD applications earlier this year after stakeholders objected to the approval process. The FDA eventually reopened the registration window for a full year, prompting a rush of items on the list and nearly tripling the original number currently under review from 3,536 to 12,118.

Few articles in the public database passed the first round of FSA review. Companies wishing to enter the UK CBD market but who have yet to meet the initial criteria can submit normal new food regulatory applications directly to the regulator.

Distances from public lists

Savage Cabbage, a British company, has withdrawn one of its products. It sells a ‘CBDa Full Spectrum Hemp Extract 30ml Natural Flavor’. “The FSA has made an intriguing ruling in advising that any product containing CBDa as its main description must have its own novel food application,” said Jade Proudman, CEO of Savage Cabbage.

“Because our Savage Cabbage CBDa oil is an exclusive compound with CBD and is not one of our broad spectrum products, it is being withdrawn from stores under this policy.” While we respect their current position, we find it annoying and don’t believe it’s up science based.”

In relation to the ACI application, she also stated that she is actively compiling the data needed to support EFSA’s new food submissions from her members. The ACI declined to provide any further information on its requests, stating that it “will wait until it receives a response from the FSA on the progress of its data package”.

So far, only a few products have been authenticated in the public database. After validation, they undergo a risk analysis before being released for sale.

On Friday November 4th, the European Industrial Hemp Association (EIHA), which represents over 170 companies with thousands of products, submitted applications to the European Food Safety Authority (EFSA) and the FSA to have their CBD isolate and synthetic Validate CBD.

Reduced daily intake

The EIHA proposal also included information on its toxicity research and, as a result of the results, recommends an Acceptable Daily Intake (ADI) of 17.5 mg CBD per day. This is significantly lower than the UK FSA’s current recommendation of 70 mg per day.

“For the isolated CBD, we found effects in four organs as well as the liver and kidney,” said EIHA Executive Director Lorenza Romanese, less than we predicted and lower than what is suggested in the existing literature.”

From this we were able to derive an Acceptable Daily Intake (ADI) of 17.5 mg CBD per day, which was proposed to the FSA and EFSA.

Increased concentration for full spectrum

She further claimed that the results of toxicological tests on its full-spectrum CBD, due to be presented early next year, would suggest a higher ADI due to its “less concentrated formulation” and “good preliminary results”.

In a letter to members, the EIHA explains that formulations must have a maximum CBD content of 10% and that other labeling standards are required, e.g.

MORE ON CHARLOTTE’S WEB, READ MORE…

THE STORY OF CHARLOTTE’S WEB CBD, WHO WAS SHE?